Literature DB >> 7340885

Serum phenytoin concentration and clinical response in patients with epilepsy.

D J Gannaway, G E Mawer.   

Abstract

1 Patients with poorly controlled epilepsy were cautiously transferred from multiple drug therapy to treatment with phenytoin sodium alone. One patient suffered more severe seizures and the initial treatment was restarted. The remainder showed no deterioration. 2 The daily dose of phenytoin was then increased by a small increment at intervals of 2 or more months. The serum phenytoin concentration (total and free) was measured regularly and response was assessed by records of seizure frequency and tests of speech, handwriting, short-term memory and coordination. 3 Patients (n = 11) with partial seizures showed no consistent improvement with increased phenytoin concentration within the range 15 mg/l (60 mumol/l) to the individual threshold for intoxication, greater than or equal to 35 mg/l (140 mumol/l). Patients (n = 4) with generalized seizures however were consistently improved at higher concentrations. 4 Tolerance to phenytoin varied, the threshold for symptomatic intoxication ranging from 35-60 mg/l (140-240 mumol/l) total and 2.7-5.2 mg/l (10.8-20.8 mumol/l) free. Ataxia was the commonest symptom and in some cases this was manifest by worsening of performance on the test of coordination (pursuit rotor). Even at lower phenytoin concentrations the patients performed less well on this test than control subjects. Other tests of performance showed no evidence of impairment at higher phenytoin concentrations. 5 The same daily dose of phenytoin tended to give higher serum drug concentrations after intoxication than before.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7340885      PMCID: PMC1401932          DOI: 10.1111/j.1365-2125.1981.tb01316.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  SIMPLE MEASURES OF HANDWRITING AS INDICES OF DRUG EFFECTS.

Authors:  D LEGGE; H STEINBERG; A SUMMERFIELD
Journal:  Percept Mot Skills       Date:  1964-04

2.  Chronic antiepileptic toxicity: a review.

Authors:  E H Reynolds
Journal:  Epilepsia       Date:  1975-06       Impact factor: 5.864

3.  Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication.

Authors:  H E Booker; B Darcey
Journal:  Epilepsia       Date:  1973-06       Impact factor: 5.864

4.  Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid.

Authors:  L Lund; A Berlin; K M Lunde
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

5.  Rapid determination of diphenylhydantoin in blood plasma by gas-liquid chromatography.

Authors:  J MacGee
Journal:  Anal Chem       Date:  1970-03       Impact factor: 6.986

6.  Transfer from multiple to single antiepileptic drug therapy.

Authors:  D J Gannaway; G E Mawer
Journal:  Lancet       Date:  1981-01-24       Impact factor: 79.321

7.  Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures.

Authors:  L Lund
Journal:  Arch Neurol       Date:  1974-11

8.  The distribution of plasma phenytoin levels in epileptic patients.

Authors:  P T Lascelles; R S Kocen; E H Reynolds
Journal:  J Neurol Neurosurg Psychiatry       Date:  1970-08       Impact factor: 10.154

9.  Unnecessary polypharmacy for epilepsy.

Authors:  S D Shorvon; E H Reynolds
Journal:  Br Med J       Date:  1977-06-25

10.  The metabolism of diphenylhydantoin (Dilantin) following once-daily administration.

Authors:  R A Buchanan; A W Kinkel; J R Goulet; T C Smith
Journal:  Neurology       Date:  1972-02       Impact factor: 9.910

View more
  13 in total

Review 1.  Drug-induced cerebellar ataxia: a systematic review.

Authors:  J van Gaalen; F G Kerstens; R P P W M Maas; L Härmark; B P C van de Warrenburg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

2.  Overuse of monitoring of blood concentrations of antiepileptic drugs.

Authors:  M J Brodie
Journal:  Br Med J (Clin Res Ed)       Date:  1987-04-25

3.  The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing.

Authors:  G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

Review 4.  Epilepsy.

Authors:  D Chadwick
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-03       Impact factor: 10.154

5.  "Therapeutic" serum concentration of phenytoin: the influence of seizure type.

Authors:  D M Turnbull; M D Rawlins; D Weightman; D W Chadwick
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-03       Impact factor: 10.154

6.  The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulation.

Authors:  Jun-jie Ding; Yun-jian Zhang; Zheng Jiao; Yi Wang
Journal:  Acta Pharmacol Sin       Date:  2012-10-29       Impact factor: 6.150

7.  Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam.

Authors:  A F Cohen; L Ashby; D Crowley; G Land; A W Peck; A A Miller
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

Review 8.  The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

9.  Epileptic seizure disorders. Developments in diagnosis and therapy.

Authors:  E Niedermeyer; W Froescher; R S Fisher
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

10.  Factors affecting the free plasma fraction of phenytoin in patients with epilepsy.

Authors:  M C Jiménez; J A Durán; J A Abad In
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.